AKTX
Akari Therapeutics PLC
NASDAQ: AKTX · HEALTHCARE · BIOTECHNOLOGY
$5.35
+2.10% today
Updated 2026-04-30
Market cap
$6.64M
P/E ratio
0.00
P/S ratio
478,368.50x
EPS (TTM)
$0.00
Dividend yield
—
52W range
$3 – $59
Volume
0.3M
Akari Therapeutics PLC (AKTX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+14.9%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+75.1%
Most recent quarter
When is the next earnings report?
Reporting date
December 31, 2025
Consensus EPS estimate
$-2.40
Fiscal period ending
2025-12-31
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-2.6%
Last 1 reports
Positive reaction rate
0%
0 of 1 quarters
Largest single-day move
-2.6%
2025-11-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2025-11-13 | $-0.20 | -81.8% | $0.54 | $0.53 | -2.6% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-2.40 | — | — | — | — |
| 2025-09-30 | $-0.11 | $-0.20 | -81.8% | — | — |
| 2025-06-30 | $-0.11 | $-0.06 | +45.5% | — | — |
| 2025-03-31 | $-1.00 | $-0.19 | +81.0% | $25998.00 | — |
| 2024-09-30 | — | $-9.50 | — | — | — |
| 2024-06-30 | — | $-0.80 | — | — | — |
| 2024-03-31 | — | $-0.83 | — | — | — |
| 2023-09-30 | $-0.60 | $0.00 | +100.0% | — | — |
| 2023-06-30 | $-1.20 | $0.00 | +100.0% | — | — |
| 2023-03-31 | $-0.07 | $-0.08 | -14.3% | — | — |
| 2022-12-31 | $-0.07 | $-0.08 | -14.3% | — | — |
| 2022-09-30 | $-0.04 | $-0.04 | +0.0% | — | — |
| 2022-06-30 | — | $-0.10 | — | — | — |
Frequently asked questions
When does Akari Therapeutics PLC report next earnings?
Akari Therapeutics PLC (AKTX) is scheduled to report earnings on December 31, 2025. The consensus EPS estimate is $-2.40.
Has Akari Therapeutics PLC beaten earnings estimates?
Akari Therapeutics PLC has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +14.9% over the last 3 quarters.
How does AKTX stock react to earnings?
AKTX stock has moved an average of -2.6% in the trading day following earnings over its last 1 reports, with positive reactions in 0% of those quarters.